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HA6 2RN, UK.
The main variables in a course of radiotherapy are the
number of fractions, the dose per fraction, the total dose'
given and the overall duration of treatment. Radiotherapists
endeavour to employ a combination which will achieve the
maximum tumour control with the minimum of normal
tissue damage. At each centre in the United Kingdom
regimes are employed in curative treatment that are based
upon clinical experience, practical considerations and local
tradition. Although,, in nearly all, daily treatment is given on
five days of the week, the number of fractions ranges from
15 to 35, the individual dose from 1.8 to 3.4Gy, the total
dose from 50 to 70Gy and the overall duration from 3 to 7
weeks.
An accumulation of data from the laboratory and from
the clinic now allows some explanation of the relationship
between these variables (Withers et al., 1982, 1988; Trott &
Kummermehr, 1984; Denekamp, 1986; Fowler, 1986;
Tubiana, 1988). In human tumours it has been possible to
determine, using flow cytometry, not only the percentage of
cells in S phase, but also the duration of S phase, and hence
the potential doubling time, by giving an intravenous
administration of bromodeoxyuridine 4-8h before tumour
sampling. Using this technique half of the human tumours
studied showed a potential to double their cell number in 5
or fewer days (Begg et al., 1985, 1988; Wilson et al., 1985,
1988). It is probable that the cells which survive the initial
treatments of a course of radiotherapy will repopulate
rapidly and replace those that have been killed. It follows
that the longer the overall duration of treatment the greater
must be the chance for repopulation to be a cause of failure.
Turning to the normal tissues, we now know that the giving
of a course of radiotherapy in many small individual doses
may spare late damage, for injury to the critical supporting
connective tissue is minimised under these conditions
(Withers et al., 1982; Thames, 1988). This knowledge may
explain why different regimes may give similar tumour
control and morbidity; however, it has also led to clinical
exploration to develop new regimes which might bring a real
advantage in tumour control.
In order to shorten the overall duration of radiotherapy
and use a small individual dose per fraction, more than one
treatment must be given on each day. There are now a
number of completed and ongoing clinical studies using
multiple treatments in one day and experience has already
shown that a normal dose increment of 2Gy cannot be
maintained while giving accelerated treatment. There are
problems with the tolerance of normal tissues and if a full
tumour dose is given early reactions may not heal and will
continue on to late morbidity (Peracchia & Salti, 1981; Van
den Bogaert et al., 1982; Dische & Saunders, 1988).
To overcome this, many workers have interrupted their
accelerated treatment in order to allow for normal tissue
recovery (Van den Bogaert et al., 1982; Wang et al., 1986;
Dische & Saunders, 1988). The rest periods have commonly
been between 2 and 4 weeks but these, and also the weekend
gap between the last treatment on Friday and the first on
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Monday, may allow considerable repopulation by surviving
tumour cells to occur.
A scheme of continuous, hyperfractionated, accelerated
radiotherapy (CHART) was devised at Mount Vernon and
took note of the biological data available (Saunders &
Dische, 1986). Radiotherapy was given three times daily for
a continuous period of 12 days. As treatment was
commenced on a Monday this required continuation through
one weekend. The time interval between treatments given on
each day was of considerable importance. If it were too
short the maximum repair of sub-lethal injury in normal
tissues would not have occurred and as a result some of the
benefit would have been lost; based on laboratory data a
period of 6 hours was chosen (Saunders et al., 1988). A pilot
study which included 128 patients was commenced in
January 1985 and completed in December 1987. An
individual dose of 1.4Gy was given to the first 38 patients so
that a total minimum tumour dose of 50.4Gy was achieved
in the 36 treatments. As tolerance appeared good the
individual dose was increased to 1.5Gy so that the total dose
given to the subsequent 90 patients was 54.0Gy (Saunders &
Dische, 1989, and unpublished).
Early radiation reactions have been well tolerated, but
where the tongue has been included and the higher doses
given, delays up to 6 months have occurred in a few cases
before final healing. An interim assessment of late changes
suggests that these may be less than after conventional
treatment.
Included were 48 patients with advanced squamous cell
cancer in the head and neck region who completed
treatment. A complete regression was apparent in 44 (92%)
of the 48 primary tumours and also in 18 (78%) of 23
patients who presented, in addition, secondary nodes. In an
analysis performed in October 1988 concerning the 37
patients with T3 and T4 tumours when comparison was
made with comparable previously treated cases at Mount
Vernon there were statistically significant improvements in
tumour control and survival (Saunders & Dische,
unpublished).
The results using CHART in 52 patients with locally
advanced carcinoma of the bronchus were also compared
with a previously treated group of 62 patients with similar
disease. Using CHART complete radiological disappearance
of tumour was obtained in 22 (42%) of the 52 patients
compared with 9 (15%) of the 62 patients in the previous
group. A review of the data in September 1988 showed that
30 (67%) of 45 patients treated more than 1 year previously
remained alive at I year; of 26 treated more than 2 years
previously 11 (42%) were alive at the 2-year interval
(Saunders & Dische, 1989). These findings can be compared
with 44 and 12% obtained in the previous study, where
results were comparable with those commonly recorded
when locally advanced bronchogenic carcinoma is treated by
radiotherapy (Perez et al., 1982; Schaake-Konig et al., 1983).
As a result of a joint Medical Research Council and
Cancer Research Campaign initiative, supported by the
D of H, the promise of the pilot study is now to be tested in
multi-centre randomised trials in bronchial and in head and
neck cancer. It is hoped that randomisation into the studies
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will begin early in 1989. If, in the phase III studies, CHART
is shown to be superior to conventional radiotherapy then
the result will have significance for the whole of oncology, as
the capacity of human tumours to repopulate rapidly will
have been confirmed. Advances should follow the reduction
of the overall duration of management from initial surgery
through to completion of radiotherapy and cytotoxic
chemotherapy.
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